DataVXAdvanced MaterialsPaper
journal article·2022-06

Antiangiogenic Nanomicelles for the Topical Delivery of Aflibercept to Treat Retinal Neovascular Disease

Xinxin Zhao, Ivan Seah, Kun Xue, Wendy Wong, Queenie Shu Woon Tan, Xiaoxiao Ma, Qianyu Lin, Jason Y. C. Lim, Zengping Liu, Bhav Harshad Parikh, Karishma N. Mehta, Joel Weijia Lai, Binxia Yang, Kim Chi Tran, Veluchamy Amutha Barathi, Kang Hao Cheong, Walter Hunziker, Xinyi Su, Xian Jun Loh

Advanced Materials· Volume 34· Issue 25
Publisher page
Source abstract

Abstract

Abstract The traditional intravitreal injection delivery of antivascular endothelial growth factor (anti‐VEGF) to the posterior segment of the eye for treatment of retinal diseases is invasive and associated with sight‐threatening complications. To avoid such complications, there has been significant interest in developing polymers for topical drug delivery to the retina. This study reports a nanomicelle drug delivery system made of a copolymer EPC (nEPCs), which is capable of delivering aflibercept to the posterior segment topically through corneal–scleral routes. EPC is composed of poly(ethylene glycol) (PEG), poly(propylene glycol) (PPG), and polycaprolactone (PCL) segments. In this study, aflibercept‐loaded nEPCs (nEPCs + A) are capable of penetrating the cornea in ex vivo porcine eye models and deliver a clinically significant amount of aflibercept to the retina in laser‐induced choroidal neovascularization (CNV) murine models, causing CNV regression. nEPCs + A also demonstrate biocompatibility in vitro and in vivo. Interestingly, this study also suggests that nEPCs have intrinsic antiangiogenic properties. The ability to deliver anti‐VEGF drugs and the intrinsic antiangiogenic properties of nEPCs may result in synergistic effects, which can be harnessed for effective therapeutics. nEPCs may be a promising topical anti‐VEGF delivery platform for the treatment of retinal diseases.
Source: crossref · Quality: baseline

Research context

PolymersNanomaterialsBiomaterials

OpenAlex topics: Retinal Diseases and Treatments · Corneal Surgery and Treatments · Ocular Surface and Contact Lens

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Molecular and Cell Biology (IMCB) Agency for Science, Technology and Research (A*STAR) 61 Biopolis Drive Singapore 138 673 Singapore

Department of Ophthalmology National University Hospital 1E Kent Ridge Road, NUHS Tower Block Level 7 Singapore 119 228 Singapore

Institute of Materials Research and Engineering (IMRE) Agency for Science, Technology and Research (A*STAR) 2 Fusionopolis Way Singapore 138 634 Singapore

Department of Ophthalmology Yong Loo Lin School of Medicine National University of Singapore 1E Kent Ridge Road, NUHS Tower Block Level 7 Singapore 119 228 Singapore

Singapore Institute of Technology (SIT) SIT@Dover 10 Dover Drive Singapore 138 683 Singapore

Science, Mathematics and Technology Cluster Singapore University of Technology and Design (SUTD) 8 Somapah Road Singapore 487 372 Singapore

Singapore Eye Research Institute (SERI) The Academia 20 College Road, Level 6 Discovery Tower Singapore 169856 Singapore

Academic Clinical Program in Ophthalmology Duke‐NUS Medical School 8 College Road Singapore 169 857 Singapore

SUTD‐Massachusetts Institute of Technology International Design Centre 8 Somapah Road Singapore 487 372 Singapore

Funding

Agency for Science, Technology and Research

References (50)

Show source-provided references
1. 10.2147/OPTH.S11400610.2147/OPTH.S114006 ↗
2. 10.1016/S2214-109X(13)70145-110.1016/S2214-109X(13)70145-1 ↗
3. 10.1186/s40942-017-0084-910.1186/s40942-017-0084-9 ↗
4. 10.2147/OPTH.S18505210.2147/OPTH.S185052 ↗
5. 10.1097/IAE.000000000000267010.1097/IAE.0000000000002670 ↗
6. 10.1097/IAE.0b013e3181633fee10.1097/IAE.0b013e3181633fee ↗
7. 10.1001/archophthalmol.2009.30410.1001/archophthalmol.2009.304 ↗
8. 10.1007/s11095-018-2519-x10.1007/s11095-018-2519-x ↗
9. 10.1007/s13346-016-0339-210.1007/s13346-016-0339-2 ↗
10. 10.1016/j.addr.2018.01.00810.1016/j.addr.2018.01.008 ↗
11. 10.1016/j.colsurfb.2016.07.00110.1016/j.colsurfb.2016.07.001 ↗
12. 10.3109/10717544.2014.90353510.3109/10717544.2014.903535 ↗
13. Alami‐Milani M. · Iran J. Basic Med. Sci. · 2018 · 21 · 153
14. 10.1080/10837450.2020.173360610.1080/10837450.2020.1733606 ↗
15. 10.1097/APO.000000000000029110.1097/APO.0000000000000291 ↗
16. 10.1038/s41551-020-00606-810.1038/s41551-020-00606-8 ↗
17. 10.1021/acs.chemrev.8b0019910.1021/acs.chemrev.8b00199 ↗
18. 10.1002/smll.20130343310.1002/smll.201303433 ↗
19. 10.1167/iovs.16-2007210.1167/iovs.16-20072 ↗
20. 10.3389/fphar.2020.0069710.3389/fphar.2020.00697 ↗
21. 10.1016/j.jconrel.2017.01.01210.1016/j.jconrel.2017.01.012 ↗
22. 10.1002/wnan.127210.1002/wnan.1272 ↗
23. 10.2174/187791231120202008210.2174/1877912311202020082 ↗
24. 10.2147/IJN.S9034710.2147/IJN.S90347 ↗
25. 10.1016/j.jconrel.2010.06.00610.1016/j.jconrel.2010.06.006 ↗
26. 10.1167/tvst.4.3.110.1167/tvst.4.3.1 ↗
27. 10.1080/10717544.2018.147497210.1080/10717544.2018.1474972 ↗
28. 10.1016/j.ejps.2015.04.00310.1016/j.ejps.2015.04.003 ↗
29. 10.1038/nrd370010.1038/nrd3700 ↗
30. 10.1038/s41551-019-0382-710.1038/s41551-019-0382-7 ↗
31. 10.1021/bm060793310.1021/bm0607933 ↗
32. 10.1016/j.molliq.2016.10.09010.1016/j.molliq.2016.10.090 ↗
33. 10.3389/fphar.2014.0007710.3389/fphar.2014.00077 ↗
34. 10.1039/C9BM01049A10.1039/C9BM01049A ↗
35. 10.1073/pnas.17239829910.1073/pnas.172398299 ↗
36. 10.1021/jp903984r10.1021/jp903984r ↗
37. 10.2217/nnm.12.17910.2217/nnm.12.179 ↗
38. 10.3390/cells1005104910.3390/cells10051049 ↗
39. 10.1371/journal.pone.006955210.1371/journal.pone.0069552 ↗
40. 10.1177/221106821456102510.1177/2211068214561025 ↗
41. 10.1136/bjophthalmol-2013-30384410.1136/bjophthalmol-2013-303844 ↗
42. 10.1007/s10456-011-9249-610.1007/s10456-011-9249-6 ↗
43. Yi X.‐j. · Invest. Ophthalmol. Visual Sci. · 2000 · 41 · 4093
44. 10.1161/01.RES.0000259593.07661.1e10.1161/01.RES.0000259593.07661.1e ↗
45. 10.1016/j.preteyeres.2010.05.00310.1016/j.preteyeres.2010.05.003 ↗
46. 10.1038/s41598-018-28745-810.1038/s41598-018-28745-8 ↗
47. 10.1039/D0MA00734J10.1039/D0MA00734J ↗
48. 10.1049/el:2008094310.1049/el:20080943 ↗
49. 10.1038/nrm223610.1038/nrm2236 ↗
50. 10.1016/j.exer.2020.10818710.1016/j.exer.2020.108187 ↗